Dentsply Sirona

XRAY · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

XRAY · Last close · October 26, 2026

$9.22

Dentsply Sirona's revenue fell 3.0% to $3.7 billion in fiscal 2025. Its operating margin was −11.5%, up from −23.2% a year earlier. Free cash flow was $104 million, down 63.0%. It paid out $128 million in dividends and buybacks, 123% of free cash flow. The diluted share count fell 1.9%.

DENTSPLY SIRONA Inc. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0000818479-26-000075 Updated October 16, 2026

Revenue

$3.7B

3.0%

Operating margin

−11.5%

11.7 pts

Net income

−$598M

Free cash flow

$104M

63.0%

Return on capital

−9.9%

6.8 pts

Market cap

$1.8B

Oct 26 close

P/E

—

Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

Revenue and margins

Revenue

US$ billions, fiscal years

Margins

Percent of revenue

GrossOperatingNetFree cash flow

Net income and earnings per share

From fiscal 2016 to 2021, earnings per share fell 0.7% a year and net income 0.9% a year, while buybacks cut the share count by 1%. Dentsply Sirona then lost money in fiscal 2022, 2023, 2024 and 2025.

Net income

US$ billions, fiscal years; loss years in red.

Diluted earnings per share

US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity

Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.

Return on capitalReturn on equity

Cash flow

Free cash flow

US$ billions. Cash from operations minus capital expenditure; negative years in red.

Payouts and share count

Dividends and buybacks

US$ billions, cash paid in each fiscal year

DividendsShare buybacks

Diluted share count

Weighted-average diluted shares, millions

Valuation

Two ways to value Dentsply Sirona yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.

Discounted cash flow (DCF)

A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Dentsply Sirona's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.

Value per share on three example scenarios, from Dentsply Sirona's fiscal 2025 free cash flow of $104M, net cash of −$1.9B at December 31, 2025 and 199 million diluted shares, from its filings. The scenarios are fitted to Dentsply Sirona: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, -2.1% a year, kept between 0% and 20%; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 11%: 9% for a business of moderate risk (Health Care Supplies), plus 1 point as a smaller company, worth $1.8B, plus 1 point for unsteady results (a loss in fiscal 2025); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target. A negative value means Dentsply Sirona's net debt is larger than what that scenario's cash flows are worth today.

From the filings

Starting free cash flow, US$ millions

Cash from operations minus capital spending in fiscal 2025.

Net cash, US$ millions

Cash and short-term investments minus debt and finance leases at December 31, 2025. Negative means net debt.

Diluted shares, millions

Weighted-average diluted shares in fiscal 2025.

Your assumptions

Start from

Fitted to Dentsply Sirona's own revenue growth, as above. Cautious: growth of -2% then 0% a year, 2% after year 10, a 12% discount rate. Base: growth of 0% then 1% a year, 2.5% after year 10, a 11% discount rate. Optimistic: growth of 2% then 2.5% a year, 3% after year 10, a 10% discount rate.

Free cash flow growth, years 1 to 5 (% a year)

Free cash flow growth, years 6 to 10 (% a year)

Growth after year 10 (% a year)Long-run growth forever after year 10. Usually close to inflation, and always below the discount rate.

Discount rate (% a year)The yearly return an investor wants for the risk. A higher rate gives a lower value.

Value per share on these assumptions

—

Last close, October 26, 2026: $9.22
Value on these assumptions, against the last close: —

Cash flows in years 1 to 10, valued today: —
Everything after year 10, valued today: —
Plus net cash: —
Share of value from after year 10: —

Projected free cash flow

US$ billions. Each column is one year's projected free cash flow, split into what it is worth today and the part removed by discounting.

Value todayRemoved by discounting

How the value changes with two assumptions

Value per share in US$, with the growth rates above. The highlighted cell matches the current assumptions.

How the model works. Free cash flow grows at the first rate for five years and the second rate for five more, and each year is discounted at the discount rate. Everything after year 10 is valued as year-10 cash flow × (1 + growth after year 10) ÷ (discount rate − growth after year 10), discounted back ten years. Net cash is added and the total is divided by diluted shares. The result depends entirely on the assumptions. It is not a forecast, a price target or a recommendation. The last close is the consolidated US closing price, from Databento.

Price-to-earnings (P/E) method

Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.

The P/E method needs positive earnings, and Dentsply Sirona's latest diluted earnings per share were negative or zero.

Balance sheet

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	339	365	334	272	326
Debt incl. finance leases	1,924	1,873	1,910	1,748	2,276
Net debt (negative means net cash)	1,585	1,508	1,576	1,476	1,950
Net debt to EBITDA	1.7x	—	6.1x	—	—
Debt to equity	0.4x	0.5x	0.6x	0.9x	1.7x
Interest coverage	10.0x	−14.4x	−1.1x	−12.7x	−4.8x
Current ratio	1.5x	1.6x	1.4x	1.1x	1.5x
Quick ratio	1.1x	1.1x	0.9x	0.7x	1.0x

US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Insider trades

Over the 12 months between October 27, 2025 and October 26, 2026, 8 insiders bought $1.6 million of Dentsply Sirona shares on the open market, and 1 insider sold $915,708.

Date	Insider	Trade	Shares	Price	Value	Filing
Jun 15, 2026	Brian T GladdenDirector	Bought	9,985	$10.02	$100,050	Form 4
Jun 15, 2026	Clyde HoseinDirector	Bought	6,500	$9.99	$64,935	Form 4
Jun 12, 2026	Brian P McKeonDirector	Bought	10,000	$10.12	$101,200	Form 4
Jun 11, 2026	Michael J BarberDirector	Bought	15,175	$9.89	$150,081	Form 4
Jun 11, 2026	Betsy D HoldenDirector	Bought	10,086	$9.88	$99,650	Form 4
Mar 9, 2026	Gregory T LucierDirector	Bought	15,000	$12.45	$186,750	Form 4
Mar 9, 2026	James D ForbesDirector	Bought	5,000	$12.48	$62,400	Form 4
Mar 3, 2026	Gregory T LucierDirector	Bought	22,445	$14.03	$314,903	Form 4
Mar 3, 2026	James D ForbesDirector	Bought	5,000	$13.47	$67,350	Form 4
Mar 2, 2026	Gregory T LucierDirector	Bought	27,555	$14.25	$392,659	Form 4
Dec 8, 2025	Gregory T LucierDirector	Sold	82,200	$11.14	$915,708	Form 4
Nov 24, 2025	Leslie F VaronDirector	Bought	9,337	$10.71	$99,999	Form 4

Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Piotroski F-score

The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.

Test	FY23	FY24	FY25
Net income is positive	Fail	Fail	Fail
Cash from operations is positive	Pass	Pass	Pass
Return on assets rose	Pass	Fail	Pass
Cash from operations exceeds net income	Pass	Pass	Pass
Debt fell relative to assets	Fail	Fail	Fail
Current ratio rose	Fail	Fail	Pass
Share count didn't rise	Pass	Pass	Pass
Gross margin rose	Fail	Fail	Fail
Revenue rose relative to assets	Pass	Fail	Pass
F-score	5 of 9	3 of 9	6 of 9
Accruals ratio	−6.8%	−20.9%	−14.9%

The accruals ratio is net income minus cash from operations, over average total assets.

Compare

Put Dentsply Sirona side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

Company	Year	Revenue growth	Operating margin	Free cash flow margin	Return on capital	Net debt to EBITDA	F-score	Compare
Dentsply Sirona	FY25	−3.0%	−11.5%	2.8%	−9.9%	—	6
Align Technology	FY25	0.9%	13.5%	12.2%	13.3%	−1.4x	5	Compare
Cooper Companies	FY25	5.1%	16.7%	10.6%	4.3%	2.3x	5	Compare
West Pharmaceutical Services	FY25	6.2%	19.0%	15.2%	18.7%	−0.8x	9	Compare
Envista	FY25	8.3%	8.0%	8.5%	3.2%	0.7x	7	Compare

Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score above.

10 years of figures

Fiscal year	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Revenue	0	3,993	3,986	4,022	3,339	4,231	3,922	3,965	3,793	3,680
Revenue growth	—	—	−0.2%	0.9%	−17.0%	26.7%	−7.3%	1.1%	−4.3%	−3.0%
Gross profit	2,001	2,188	2,068	2,164	1,656	2,347	2,127	2,086	1,958	1,840
Research and development	128	152	161	143	123	171	174	184	165	150
Operating income	455	−1,562	−958	353	−3	608	−937	−85	−879	−422
Net income	430	−1,550	−1,011	256	−73	411	−950	−132	−910	−598
Diluted EPS (US$)	1.94	−6.76	−4.51	1.14	−0.33	1.87	−4.41	−0.62	−4.48	−3.00
Diluted shares (millions)	222	229	224	224	219	220	216	212	203	199
Cash flow
Cash from operations	563	602	500	639	649	657	517	377	461	235
Capital expenditure	125	144	183	123	87	142	149	149	180	131
Free cash flow	438	458	317	516	562	515	368	228	281	104
Dividends paid	65	78	79	81	88	92	104	116	126	128
Share buybacks	814	401	250	260	140	200	150	300	250	0
Acquisitions	342	146	130	3	1,078	248	0	0	0	0
Stock-based compensation	41	48	21	66	47	48	59	46	39	33
Balance sheet at fiscal year end
Cash and short-term investments	384	321	310	405	438	339	365	334	272	326
Debt incl. finance leases	1,528	1,626	1,580	1,440	2,285	1,924	1,873	1,910	1,748	2,276
Total assets	11,556	10,374	8,687	8,603	9,350	9,239	7,643	7,370	5,753	5,429
Total liabilities	3,430	3,747	3,554	3,508	4,415	4,242	3,831	4,076	3,810	4,089
Shareholders' equity	8,114	6,616	5,121	5,093	4,932	4,996	3,811	3,293	1,942	1,339
Margins and ratios
Gross margin	—	54.8%	51.9%	53.8%	49.6%	55.5%	54.2%	52.6%	51.6%	50.0%
Operating margin	—	−39.1%	−24.0%	8.8%	−0.1%	14.4%	−23.9%	−2.1%	−23.2%	−11.5%
Net margin	—	−38.8%	−25.4%	6.4%	−2.2%	9.7%	−24.2%	−3.3%	−24.0%	−16.2%
Free cash flow margin	—	11.5%	8.0%	12.8%	16.8%	12.2%	9.4%	5.8%	7.4%	2.8%
Return on capital	7.1%	−14.3%	−10.6%	4.3%	−0.0%	6.9%	−12.4%	−1.3%	−16.8%	−9.9%
Return on equity	8.2%	−21.0%	−17.2%	5.0%	−1.5%	8.3%	−21.6%	−3.7%	−34.8%	−36.5%
Return on assets	5.4%	−14.1%	−10.6%	3.0%	−0.8%	4.4%	−11.2%	−1.8%	−13.9%	−10.7%
Net debt to EBITDA	1.6x	—	—	1.5x	5.6x	1.7x	—	6.1x	—	—

US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)

Source: Dentsply Sirona's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Dentsply Sirona.